Pathogenesis, evaluation and pathogenetic therapy of diabetic polyneuropathy
https://doi.org/10.14412/2074-2711-2021-3-99-106
Abstract
The increase in the number and life expectancy of patients with diabetes mellitus (DM) worldwide determines the high prevalence of late complications of diabetes, including diabetic polyneuropathy (DPN), the most common type of polyneuropathy. Oxidative stress is considered the main reason for the cellular pathology development in diabetes mellitus, which determines the use of antioxidants for the DPN treatment. Alpha-lipoic acid (ALA), a natural fat-soluble antioxidant, is the most effective drug for reducing DPN symptoms. Furthermore, the symptom-modifying effect of ALA has been shown in numerous randomized controlled trials. The article discusses the possible disease-modifying effect of ALA.
Keywords
diabetes mellitus,
diabetic polyneuropathy,
evaluation,
pathogenetic therapy,
alpha-lipoic acid,
symptom-modifying treatment,
disease-modifying treatment
Supporting agencies: This article has been supported by Kanonfarma prodakshn
About the Authors
I. A. Strokov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Igor Alekseyevich Strokov
Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine
11, Rossolimo St., Build. 1, Moscow 119021
V. V. Oganov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine
11, Rossolimo St., Build. 1, Moscow 119021
References
1. Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA. 2017 Jun 27;317(24):2515-23. doi: 10.1001/jama.2017.7596
2. International Diabetes Federation Atlas. 8th ed. 2017. Available from: https://diabetesatlas.org/upload/resources/previous/files/8/IDF_DA_8e-EN-final.pdf
3. Kotov SV, Kalinin AP, Rudakova IG. Diabeticheskaya neyropatiya [Diabetic neuropathy]. Moscow: MIA; 2011. 438 p. (In Russ.).
4. Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33(10):2285-93. doi: 10.2337/dc10-1303
5. Babizhayev MA, Nosikov VV, Strokov IA, et al. The role of oxidative stress in diabetic neuropathy: generation of free radical species in the glycation reaction and gene polymorphisms encoding antioxidant enzymes to genetic susceptibility to diabetic neuropathy in population of type I diabetic patients. Cell Biochem Biophys. 2015 Apr;71(3):1425-43. doi: 10.1007/s12013-014-0365-y
6. Strokov IA, Bursa TR, Drepa OI, et al. Predisposing genetic factors for diabetic polyneuropathy in patients with type 1 diabetes: a population-based case-control study. Acta Diabetol. 2003 Dec;40 Suppl 2:S375-9. doi: 10.1007/s00592-003-0123-x
7. Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014 Aug;14(8):473. doi: 10.1007/s11910-014-0473-5
8. Strokov IA, Melnichenko GA, Albekova ZhS, et al. The prevalence and risk factors of diabetic polyneuropathy in inpatients with type 1 diabetes. Nervno-myshechnyye bolezni = Neuromuscular Diseases. 2012;(1):25-31. doi: 10.17650/2222-8721-2012-0-1-25-31 (In Russ.).
9. The DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995 Apr 15;122(8):561-8. doi: 10.7326/0003-4819-122-8-199504150-00001
10. Callaghan BC, Little AA, Feldman EL, et al. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012 Jun 13;6(6):CD007543. doi: 10.1002/14651858.CD007543.pub2
11. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes. 2005 Jun;54(6):1615-25. doi: 10.2337/diabetes.54.6.1615
12. Edwards JL, Vincent AM, Cheng HT, et al. Diabetic neuropathy: mechanisms to management. Pharmacol Ther. 2008 Oct;120(1):1-34. doi: 10.1016/j.pharmthera.2008.05.005. Epub 2008 Jun 13.
13. Zotova EV, Savost'yanov KV, Chistyakov DA, et al. Association of polymorphic markers of the antioxidant enzyme genes with diabetic polyneuropathy in type 1 diabetes mellitus. Molekulyarnaya biologiya. 2004;(2):244-9 (In Russ.).
14. Zotova EV, Chistyakov DA, Savost'yanov KV, et al. Study of the association of polymorphic markers Ala (-9) Val of the SOD2 gene and Arg213Gly of the SOD3 gene with diabetic polyneuropathy in patients with type 1 diabetes mellitus. Molekulyarnaya biologiya. 2003;(3):345-8 (In Russ.).
15. Malic RA, Tesfaye S, Thompson SD, et al. Microangiopathy in human diabetic neuropathy: relationship between capilliary abnormalities and severity of neuropathy. Diabetologia. 1993 May;36(5):454-9. doi: 10.1007/BF00402283
16. Giannini C, Dyck PJ. Ultrastructural morphometric features in human sural nerve microvessels. J Neuropathol Exp Neurol. 1993 Jul;52(4):361-9. doi: 10.1097/00005072-199307000-00003
17. Caneron NE, Cotter MA. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr Drug Targets. 2008 Jan;9(1):60-7. doi: 10.2174/138945008783431718
18. Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006 Jul;108(5):477-81. doi: 10.1016/j.clineuro.2005.08.003. Epub 2005 Sep 16.
19. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb;14(2):162-73. doi: 10.1016/S1474-4422(14)70251-0. Epub 2015 Jan 7.
20. Vincent AM, Callaghan BC, Smith AL, et al. Fiabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011 Sep 13;7(10):573-83. doi: 10.1038/nrneurol.2011.137
21. Boulton AJ, Kempler P, Ametov A, et al. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab Res Rev. 2013 Jul;29(5):327-33. doi: 10.1002/dmrr.2397
22. Strokov IA, Manukhina EB, Bakhtina LYu, et al. The function of endogenous protective systems in patients with insulin-dependent diabetes mellitus and polyneuropathy: effect of antioxidant therapy. Byulleten' eksperimental'noy biologii i meditsiny. 2000;130(10):437-41 (In Russ.).
23. Borcea V, Nourooz-Zadeh J, Wolff SP, et al. Alpha-lipoic acid decreases oxidative stress in patients with diabetes mellitus. Free Radic Biol Med. 1999 Jun;26(11-12):1495-500. doi: 10.1016/s0891-5849(99)00011-8
24. Haak ES, Usadel KH, Kohleisen M, et al. The effect of α-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy. Microvasc Res. 1999 Jul;58(1):28-34. doi: 10.1006/mvre.1999.2151
25. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant α-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995 Dec;38(12):1425-33. doi: 10.1007/BF00400603
26. Strokov IA, Kozlova NA, Mozolevskiy YuV. The efficacy of intravenous administration of thioctic (α-lipoic) acid trometamol salt in diabetic neuropathy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 1999;(6):18-22 (In Russ.).
27. Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with antioxidant α-lipoic acid: a meta-analysis. Diabet Med. 2004 Feb;21(2):114-21. doi: 10.1111/j.1464-5491.2004.01109.x
28. Ruhnau KJ, Meissner HP, Finn JR, et al. Effect of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diab Med. 1999 Dec;16(12):1040-3. doi: 10.1046/j.1464-5491.1999.00190.x
29. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care. 2006 Nov;29(11):2365-70. doi: 10.2337/dc06-1216
30. Strokov IA, Fokina AS, Golovacheva VA, Kochetov AG. Efficacy of thiolepta in diabetic polyneuropathy: results of the study ETIKA. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2013;113(5):36-40 (In Russ.).
31. Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetic Care. 2017 Jan;40(1):136-54. doi: 10.2337/dc16-2042
32. Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATAN 1 trial. Diabetes Care. 2011 Sep;34(9):2054-60. doi: 10.2337/dc11-0503. Epub 2011 Jul 20.
33. Strokov IA, Novosadova MV, Lavrova IN, et al. The prolonged clinical effect of tioctic acid in symptomatic distal diabetic polyneuropathy. Abstr. of the 14th Annual Scientific Meeting of the DFSG and NEURODIAB, Regensburg, Germany, September 2–5 2004; 195 p.
34. Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with antioxidant thioctic acid (alpha-lipoic acid): a two-year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Rad Res. 1999 Sep;31(3):171-9. doi: 10.1080/10715769900300721
Review
For citations:
Strokov IA, Oganov VV. Pathogenesis, evaluation and pathogenetic therapy of diabetic polyneuropathy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(3):99-106. (In Russ.) https://doi.org/10.14412/2074-2711-2021-3-99-106
Views:
702
Email this article 